These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6694625)

  • 1. A pilot study of flutamide. A new agent in the treatment of advanced prostatic cancer.
    Sarfaty GA; Alder SJ; McLean RG
    Med J Aust; 1984 Feb; 140(4):219-21. PubMed ID: 6694625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of flutamide as monotherapy in the treatment of advanced prostate cancer.
    Newling DW
    Prog Clin Biol Res; 1989; 303():117-21. PubMed ID: 2674980
    [No Abstract]   [Full Text] [Related]  

  • 3. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Lunglmayr G
    Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced prostatic cancer with flutamide.
    Sanford EJ; Bowditch RR; Rohner TJ; Bardin CW
    Pa Med; 1979 Sep; 82(9):29-31. PubMed ID: 386212
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new antiprostatic agent for treatment of prostatic carcinoma.
    Irwin RJ; Prout GR
    Surg Forum; 1973; 24():536-7. PubMed ID: 4806089
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
    Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
    Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
    Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
    Prog Clin Biol Res; 1989; 303():161-7. PubMed ID: 2674982
    [No Abstract]   [Full Text] [Related]  

  • 14. Flutamide therapy for advanced prostatic cancer: a phase II study.
    MacFarlane JR; Tolley DA
    Br J Urol; 1985 Apr; 57(2):172-4. PubMed ID: 3986452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 18. [Flutamide in the treatment of advanced carcinoma of the prostate].
    Vomácka V; Vachalovský V
    Rozhl Chir; 1985 Nov; 64(11):723-8. PubMed ID: 4089703
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with flutamide in previously untreated patients with advanced prostatic cancer.
    Sogani PC; Whitmore WF
    J Urol; 1979 Nov; 122(5):640-3. PubMed ID: 501817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of flutamide in the treatment of carcinoma of the prostate stages C and D (T3-T4, Nx-N0, M0-M1 categories)].
    Daricello G; Caramia G; Rizzo FP; Serretta V; Di Trapani D; Pavone-Macaluso M
    Minerva Urol Nefrol; 1986; 38(1):71-6. PubMed ID: 3738681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.